Untreated PTSD Sleep — Noradrenergic Storm in REM
Trauma memory replay is fueled by excess noradrenergic tone during REM sleep.
- 6–7: Nightmare nights/wk (typical untreated PTSD)
- High: REM noradrenaline (excess locus coeruleus tone)
- Poor: Sleep continuity (frequent awakenings)
- Elevated: Daytime hyperarousal (carries into waking hours)
Why nightmares recur
Overactive locus coeruleus floods REM sleep with norepinephrine, replaying trauma.
Hyperarousal cycle
Poor sleep worsens daytime arousal, reinforcing the nightly nightmare cycle.
Starting Prazosin — Low Dose, Bedtime, Gradual Increase
Treatment begins low and rises slowly to limit first-dose blood pressure drops.
- 1 mg: Starting dose (bedtime, first-dose caution)
- weekly: Titration step (gradual upward adjustment)
- 1–20 mg: Target range (individualized ceiling)
- Watch: First-dose effect (orthostatic drop risk)
Slow, cautious ramp
Dose rises gradually across days to weeks, monitoring tolerability closely.
First-dose caution
Initial doses carry the highest orthostatic hypotension risk.
Blocking Alpha-1 Receptors During Sleep
Prazosin blocks alpha-1 receptors, muting noradrenergic signaling overnight.
- Alpha-1 blocker: Mechanism (selective antagonist)
- CNS + vascular: Site of action (brain and periphery)
- Days: Onset of effect (dose-dependent ramp)
- ~70–90%: Blockade at target dose (estimated occupancy)
Receptor occupancy
Higher doses occupy more alpha-1 receptors, further muting REM signaling.
Selective action
Blockade targets noradrenergic overdrive without sedating the brain broadly.
Nightmare Frequency Falls With Effective Blockade
As titration reaches an effective dose, nightmare nights become far less frequent.
- 1–2: Nightmare nights/wk (at effective dose)
- 2–4 wks: Response window (to reach effect)
- Marked: Symptom relief (frequency and intensity both drop)
- Improved: Sleep quality (fewer awakenings)
Dose-response benefit
Nightmare frequency falls steadily as blockade rises toward target.
Calendar view
Weekly nightmare nights thin out visibly across the titration timeline.
Balancing Nightmare Relief Against Orthostatic Risk
Higher doses help sleep more but raise orthostatic hypotension risk modestly.
- Improved: Sleep outcome (less distress, better continuity)
- Dose-dependent: Hypotension risk (rises modestly with dose)
- BP checks: Monitoring (especially after dose increases)
- Favorable: Net benefit (when titrated carefully)
Finding the balance
The effective dose maximizes nightmare relief while limiting hypotension risk.
Ongoing care
Careful titration and monitoring sustain benefit long term.